<DOC>
	<DOCNO>NCT00017160</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy , radiation therapy , surgery may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy , radiation therapy , surgery treating patient primary recurrent sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Radiation Therapy , Surgery Treating Patients With Primary Recurrent Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall survival patient primary recurrent retroperitoneal sarcoma treat neoadjuvant doxorubicin ifosfamide , radiotherapy , surgical resection . - Assess local-regional control patient treat regimen . - Determine disease-free survival patient treat regimen . - Determine pathologic response patient treat regimen . - Determine toxic effect regimen patient . - Determine complication patient treat regimen . OUTLINE : Patients receive doxorubicin IV continuously day 1-3 ifosfamide IV 3 hour day 1-4 . Patients also receive filgrastim ( G-CSF ) begin day 5 continue blood count recover . Treatment repeat every 21 day maximum 4 course absence unacceptable toxicity . Beginning 2-4 week chemotherapy , patient undergo radiotherapy daily , 5 day week , 5-6 week . Beginning 4-7 week radiotherapy , patient undergo complete surgical resection intraoperative postoperative radiotherapy brachytherapy . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 48 patient accrue study within 24 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary recurrent soft tissue sarcoma retroperitoneum pelvis No rhabdomyosarcoma , extraosseous Ewing 's sarcoma , primitive neuroectodermal tumor , osteosarcoma , chondrosarcoma , Kaposi 's sarcoma , aggressive fibromatosis No sarcoma allow sparing twothirds 1 kidney within plan irradiation field Radiographically measurable disease great 5 cm ( T2 ) CT scan MRI abdomen pelvis Highgrade ( grade 3/3 , 3/4 , 4/4 ) disease great 5 cm OR Moderategrade ( grade 2/3 , 2/4 ) recurrent disease great 10 cm Eligible gross total resection ( R0 R1 ) No prior subtotal ( R2 ) resection Partial debulking OR subtotal tumor resection residual gross disease Fewer 4 equivocal pulmonary lesion less 3 mm diameter CT scan No multifocal disease suggestive regional nodal involvement No metastases PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 02 Life expectancy : At least 2 year Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST great 3 time upper limit normal Albumin least 3.5 g/dL Renal : Creatinine great 1.6 mg/dL Two functional kidney Cardiovascular : No congestive heart failure No myocardial infarction within past 6 month No New York Heart Association class III IV heart disease Ejection fraction least 50 % Other : No malignancy within past 5 year except surgically treat carcinoma situ cervix basal cell squamous cell skin cancer No serious medical psychiatric illness would preclude study entry No obvious bowel obstruction No hypersensitivity E. coliderived product Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Oral caloric intake least 1,500 kCal/day PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior doxorubicin ifosfamide No prior chemotherapy sarcoma Endocrine therapy : Not specify Radiotherapy : No prior abdominal pelvic irradiation Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>